SCYX
What one share of SCYNEXIS holds
Pharmaceutical Preparations
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections.
SCYNEXIS’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.50 |
|---|---|
| Profit | −$1.33 |
| Cash and investments | $1.05 |
| Book value | $6.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | $16.92 | −$214.88 | $9.49 | −$137.12 | — | $314.20 |
| 2015 | $1.69 | −$214.56 | $3.87 | −$165.31 | — | $241.34 |
| 2016 | $1.08 | −$126.04 | $0.11 | −$123.48 | — | $113.19 |
| 2017 | $0.77 | −$74.96 | $0.01 | −$73.45 | — | $59.12 |
| 2018 | $0.47 | −$22.73 | $1.03 | −$52.66 | — | $52.07 |
| 2019 | $0.17 | −$76.62 | $0.00 | −$54.38 | — | $10.59 |
| 2020 | $0.00 | −$41.18 | $0.00 | −$36.83 | — | $9.26 |
| 2021 | $3.99 | −$9.97 | $0.00 | −$16.54 | — | $11.50 |
| 2022 | $0.96 | −$11.79 | — | −$15.00 | — | $0.79 |
| 2023 | $23.17 | $11.08 | — | $9.95 | — | $15.69 |
| 2024 | $0.62 | −$3.51 | — | −$3.96 | — | $11.60 |
| 2025 | $3.30 | −$1.38 | — | −$0.85 | — | $9.07 |